Dr. Petrylak on important updates in bladder cancer from NY GU 2022

For the third consecutive year, Yale Medicine Urology, in connection with Yale New Haven Hospital, has been ranked nationally on U.S. News & World Report’s “Best Hospitals Adult Specialty” list.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

"In the last decade, we've observed a high number of new alternatives within clinical trials, especially with intravesical delivery," says Félix Guerrero-Ramos, MD, PhD, FEBU.

"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.

"This information, and future expansions of this work could help refine the ways in which key clinical decisions are made..." says Michael S. Leapman, MD, MHS.

“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.